This module captures the shared downstream cAMP/PKA segment for somatotroph pituitary adenoma mechanisms. Disorder entries should keep the gene-specific upstream lesion explicit, then declare conformance on the convergent cAMP/PKA nodes. AIP reaches the module through reduced inhibitory/catabolic restraint; GPR101 reaches it primarily through GPCR dosage gain; GNAS reaches it through constitutive Gs-alpha activity. Reported GPR101 point variants should conform to this module only when their causal status is supported in the disorder entry.
Increased somatotroph cAMP availability
convergence point
Somatotroph-lineage cells have increased intracellular cAMP availability because cAMP synthesis is increased, inhibitory restraint is reduced, cAMP degradation is reduced, or a combination of these mechanisms applies.
Downstream
-
Increased cAMP/PKA signaling in somatotrophs
Increased cAMP availability activates the cAMP/PKA signaling cassette in somatotroph-lineage cells.
Increased cAMP/PKA signaling in somatotrophs
central effector
Elevated cAMP activates protein kinase A and downstream transcriptional effectors in somatotroph-lineage cells, creating a shared proliferative and secretory signaling state across multiple genetic etiologies.
Downstream
-
Increased growth hormone secretion
cAMP/PKA signaling increases the secretory drive of somatotroph-lineage pituitary tumor cells.
-
Somatotroph proliferation and adenoma growth
cAMP/PKA signaling contributes to proliferation of somatotroph-lineage cells and growth of GH-secreting pituitary adenomas.
Increased growth hormone secretion
consequence
Somatotroph-lineage cells release excess growth hormone downstream of cAMP/PKA overactivation, producing biochemical growth hormone excess and the clinical gigantism/acromegaly spectrum.
Somatotroph proliferation and adenoma growth
consequence
cAMP-responsive somatotroph-lineage cells expand, producing pituitary hyperplasia or GH-secreting adenoma growth depending on the initiating genetic context and timing.